These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33887472)

  • 21. Systemic sclerosis with associated interstitial lung disease: management considerations and future directions.
    Bernstein EJ; Huggins JT; Hummers LK; Owens GM
    Am J Manag Care; 2021 May; 27(7 Suppl):S138-S146. PubMed ID: 34003617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Modern drug therapy for systemic sclerosis associated interstitial lung disease].
    Aringer M; Koschel D; Krause A; Schneider U; Gläser S
    Dtsch Med Wochenschr; 2022 Feb; 147(4):179-186. PubMed ID: 34861699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
    Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
    Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on scleroderma-associated interstitial lung disease.
    Fan MH; Feghali-Bostwick CA; Silver RM
    Curr Opin Rheumatol; 2014 Nov; 26(6):630-6. PubMed ID: 25191993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
    Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
    Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
    Jain S; Shahane A; Derk CT
    Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
    Fathi N; Furst DE; Clements PJ
    Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope.
    Hinchcliff M; O'Reilly S
    Curr Rheumatol Rep; 2020 Jun; 22(8):42. PubMed ID: 32562016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic sclerosis: from pathogenesis to targeted therapy.
    Denton CP
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S3-7. PubMed ID: 26457375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.